Discover how Sarah Cannon reimagined CAR-T delivery—improving patient experience and easing hospital capacity constraints with a safe, scalable at-home model.
Bring care episodes for specialty and high-cost drugs and infusions into home and community settings.
Leverage our evidence-based model to improve safety, scale, and speed.
Many providers have already taken the first step toward outpatient models for cell and gene therapy. But delivering these therapies safely and sustainably in the home requires more than a clinical protocol—it takes the right infrastructure.
We’ve partnered with leading cancer centers and pharmaceutical companies to move advanced therapies, including CAR-T, safely into the home. With therapy-specific protocols, neurotoxicity monitoring, and 24/7 clinical oversight, our model helps you expand outpatient eligibility without compromising safety or outcomes.
For years, our clinical research team has been partnering closely with our customers to conduct research on service evaluation and showcase clinical, operational and financial success.
We know what works, and those learnings are baked into our care episodes.
These are some of the research questions we’ve helped answer:
Our solution can be safely relied up on to deliver a virtual immunotherapy program and reduce hospital LOS.
Successful outpatient care depends on multidisciplinary teams, rapid response protocols for managing toxicities like CRS and ICANS, and efficient patient transitions to higher-level care when needed.
A 15-day period is sufficient for capturing nearly all serious adverse events related to FDA-approved CAR-T products, supporting a shorter, efficient monitoring approach.
Built for the highest-risk patients, designed to keep them safe at home, and proven to help you scale advanced therapies without compromise. Our model strengthens your connection to patients while preserving revenue and clinical oversight under your brand.
Designed around the unique safety profiles of complex therapies and infusion.
Care remains under your brand and clinicians, strengthening patient relationships and preserving network integrity.
Proven to save bed days and optimize hospital resources, with early adopters transitioning 75%+ of CAR-T to outpatient care while maintaining safety.
Built to fit your reimbursement and operations, our model shares risk and uses bundled options to ensure growth works in your favor.
Your clinical operating system for better experiences.
Each with predefined patient journeys, alarm parameters, and escalation protocols, ready to deploy from day one.
Our proprietary FDA-cleared continuous wearable and connected devices feed real-time data into a centralized clinical dashboard for timely interventions.
Integrated end-to-end device deployment and reprocessing in fully outsourced or hybrid models.
Put clinical insights where care teams need them—right in your EHR. Turbocharger packages for Epic support fast implementation.
Our RNs and MAs provide continuous oversight, escalating to your care team as needed to maintain safety and staffing efficiency.
Address CRS sooner with our comprehensive solution, which can detect signs of CRS more than 3 hours earlier than standard of care.
Workflows to support detection of early signs of immune effector cell-associated neurotoxicity.
On-demand lab draws and diagnostic testing performed through partners at the patient’s home to ensure timely clinical decision-making without requiring hospital visits.
In the coming weeks, our complex drug and infusion episodes will include daily, integrated ICANS assessments by our Clinical Command Center.
Discover how Sarah Cannon reimagined CAR-T delivery—improving patient experience and easing hospital capacity constraints with a safe, scalable at-home model.
Of CAR-T patients now cared for in outpatient setting
Reduction in LOS for patients requiring inpatient care
Bed days saved in first 100 patients
